Abstract:Herein, we communicate our recent medicinal chemistry efforts which have culminated in a series of PI3K delta/gamma dual inhibitors structurally featuring a seven-membered spirocyclic spacer. Compound 26, the most potent one among them, exhibited superior PI3K delta inhibitory activity (IC50 = 1.0 nM) to that of the approved PI3K delta inhibitor Idelalisib. Besides, it exerted remarkable anti-proliferative efficacy against human malignant B-cell line SU-DHL-6 with GI(50) value of 33 nM. The biochemical assay against the other three class I PI3K isoforms identified compound 26 as a potent PI3K delta/gamma dual inhibitor with considerable selectivity over PI3K alpha and PI3K beta. In SU-DHL-6 cells, a dramatic down-regulation of PI3K signaling was observed following compound 26-treatment at the concentration as low as 10 nM. Inspiringly, the pharmacokinetic (PK) study in Sprague-Dawley (SD) rats revealed it was orally available with a favorable bioavailability (F = 87.5%). Overall, compound 26, a promising PI3K delta/gamma dual inhibitor, has the potential to emerge as a clinical candidate for the treatment of leukocyte-mediated malignancies after extensive functional investigation. (c) 2020 Elsevier Masson SAS. All rights reserved.

Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.

Novel 6-Aryl Substituted 4-Pyrrolidineaminoquinazoline Derivatives As Potent Phosphoinositide 3-Kinase Delta (pi3kδ) Inhibitors.

Introduction of Pyrrolidineoxy or Piperidineamino Group at the 4-Position of Quinazoline Leading to Novel Quinazoline-Based Phosphoinositide 3-Kinase Delta (pi3kδ) Inhibitors.

Design and Synthesis of Novel 6-Aryl Substituted 4-Anilinequinazoline Derivatives As Potential PI3Kδ Inhibitors

Synthesis and Antitumor Activity Evaluation of 4,6-Disubstituted Quinazoline Derivatives As Novel Pi3k Inhibitors

Conformationally Restricted Quinazolone Derivatives As PI3Kδ-selective Inhibitors: the Design, Synthesis and Biological Evaluation.

Design, Synthesis and Biological Evaluation of Novel Selective PI3Kδ Inhibitors Containing Pyridopyrimidine Scaffold.

Design, Synthesis, and Biological Evaluation of Novel 3-Substituted Imidazo[1,2-A]pyridine and Quinazolin-4(3H)-one Derivatives As PI3Kα Inhibitors.

Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies

Identification of Novel Piperazinylquinoxaline Derivatives As Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors

Discovery of 6-benzamide Containing 4-phenylquinazoline Derivatives as Novel PI3Kδ Inhibitors

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Design And Synthesis Of A Novel Series Of N,4-Diphenylpyrimidin-2-Amine Derivatives As Potent And Selective Pi3k Gamma Inhibitors

6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine Derivatives As Selective Inhibitors of PI3Kα

Discovery of Novel Quinazoline Derivatives As Potent PI3Kδ Inhibitors with High Selectivity.

Synthesis and Biological Evaluation of Novel 2-Arylamino-3-(arylsulfonyl)quinoxalines As PI3Kα Inhibitors

Discovery of Novel Pyrido[3,2-D]pyrimidine Derivatives As Selective and Potent PI3Kδ Inhibitors.

Design, Synthesis and Biological Evaluation of Novel 4-Alkynyl-quinoline Derivatives As PI3K/mTOR Dual Inhibitors.

Design, Synthesis and Biological Evaluation of 4-Aryl-5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one Derivatives As a PI3Kα Inhibitor.

Discovery and Synthesis of a Novel Series of Potent, Selective Inhibitors of the PI3Kα: 2-Alkyl-chromeno[4,3-c]pyrazol-4(2h)-one Derivatives.

Discovery of Pyrazolo[1,5- a ]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors